David Flemming, MD
Internal Medicine · Pearl, MSNPI 1093726739
Payments from drug & device makers
Across 418 payments — averaging $15.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Pfizer$773
- Novo Nordisk$704
- Takeda Pharmaceuticals U.S.A., Inc.$561
- Amgen$429
- Lilly USA, LLC$398
- plus $2K from 27 others
What the payments were for
- Food & beverage$6,531100%
- Education$90%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 85 | $1,342 |
| Pfizer | 51 | $773 |
| Novo Nordisk | 49 | $704 |
| Takeda Pharmaceuticals U.S.A., Inc. | 33 | $561 |
| Amgen | 25 | $429 |
| Lilly USA, LLC | 26 | $398 |
| Merck | 28 | $392 |
| AstraZeneca | 23 | $381 |
| Boehringer Ingelheim | 24 | $341 |
| GSK | 13 | $211 |
| Novartis | 9 | $177 |
| Teva Pharmaceuticals USA, Inc. | 7 | $108 |
| Amarin Pharma, Inc. | 5 | $95 |
| E.r. Squibb & Sons, L.L.C. | 7 | $90 |
| Kowa Pharmaceuticals America, Inc. | 4 | $59 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $49 |
| Astellas Pharma US Inc | 3 | $49 |
| Phathom Pharmaceuticals, Inc. | 2 | $47 |
| Exact Sciences | 3 | $44 |
| Inspire Medical Systems, Inc. | 1 | $33 |
| Otsuka America Pharmaceutical, Inc. | 1 | $30 |
| Idorsia Pharmaceuticals US Inc | 2 | $29 |
| Amneal Pharmaceuticals LLC | 2 | $26 |
| Ironwood Pharmaceuticals, Inc | 2 | $26 |
| Nalpropion Pharmaceuticals LLC | 2 | $26 |
| Arbor Pharmaceuticals, Inc. | 2 | $23 |
| Lundbeck LLC | 1 | $17 |
| Johnson & Johnson | 1 | $14 |
| Eisai Inc. | 1 | $14 |
| Corium, LLC | 1 | $14 |
| Medtronic | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
| Abbott | 1 | $13 |
How this compares
$6,540 in reported general payments places this provider in the 90th percentile of 846 internal medicine providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 160 | $165,468 |
| EliquisApixaban | 184 | $164,003 |
| JardianceEmpagliflozin | 169 | $156,375 |
| JanuviaSitagliptin Phosphate | 95 | $86,690 |
| FarxigaDapagliflozin Propanediol | 90 | $68,294 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 99 | $64,737 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 92 | $59,993 |
| LinzessLinaclotide | 62 | $44,627 |
| MounjaroTirzepatide | 43 | $40,265 |
| XareltoRivaroxaban | 52 | $32,929 |
| JanumetSitagliptin Phos/Metformin Hcl | 42 | $32,768 |
| Tresiba Flextouch U-200Insulin Degludec | 36 | $26,590 |
| RybelsusSemaglutide | 20 | $26,327 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 15 | $23,213 |
| GlyxambiEmpagliflozin/Linagliptin | 24 | $19,450 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Combivent Respimat, Glyxambi, Tradjenta, Synjardy Xr | $341 | $227,749248 claims |
| Novo NordiskOzempic, Rybelsus | $704 | $191,795180 claims |
| MerckJanuvia, Janumet Xr, Janumet, Belsomra | $392 | $187,826243 claims |
| PfizerEliquis | $773 | $164,003184 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $211 | $81,692135 claims |
| AstraZenecaFarxiga, Symbicort | $381 | $76,092120 claims |
| AbbVieLinzess, Synthroid, Qulipta | $1,342 | $74,800322 claims |
| Lilly USA, LLCMounjaro | $398 | $40,26543 claims |
| Johnson & JohnsonXarelto | $14 | $32,92952 claims |
| Astellas Pharma US IncMyrbetriq | $49 | $16,77019 claims |
| NovartisEntresto | $177 | $11,04421 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $561 | $10,89421 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 846 internal medicine providers in Mississippi.
Other internal medicine in Pearl
- James HallBrookhaven$4.8M
- Bob HutchinsJackson$4.6M
- Sidney GortonBelzoni$571K
- David PendleyGulfport$336K
- Sarah KerutJackson$319K
- Gabriel HernandezJackson$196K
- Kelly WilkinsonJackson$183K
- Magdy Gorgi-MikhailBiloxi$157K
- Christina BarlowJackson$129K
- Arnold JacksonHattiesburg$121K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.